2019 —

07.09.19/ Dermata Therapeutics, LLC Announces Positive Results from a Phase 1 Clinical Trial of DMT410, A New Topical Delivery Mechanism for Botulinum Toxin

Dermata completed a Phase 1 study of their new combination regimen, DMT410, using their DMT310 sponge product in combination with botulinum toxin for the treatment of primary axillary hyperhidrosis and received excellent results.

Read more here link.

2017 —

04.13.17 / Dermata Therapeutics, LLC and Villani, Inc. Announce a Global License Agreement for a Natural Sponge Product for Skin Diseases

Dermata has entered into an exclusive worldwide license agreement with Villani to develop Villani's natural sponge product (now DMT310) for various skin diseases.  The first target for Dermata will be to study DMT310 for moderate to severe acne vulgaris.

Read more here link.

02.16.17 / Dermata Therapeutics Closes a $5 Million Series 1a Financing and Secures a $5 Million Credit Facility from Silicon Valley Bank

Dermata has finalized its most recent round of financing with the close of a Series 1a financing from management and high net worth individuals.  They also closed on a $5 Million credit facility from Silicon Valley Bank where they received $2.5 million and will receive the remaining $2.5 million after successful completion of certain milestones. 

Read more here link.

01.18.17 / Dermata Therapeutics, LLC Announces Initiation of Treatment in a Phase 2 Acne Rosacea Clinical Study

Today, Dermata began dosing patients in a Phase 2 Acne Rosacea study.   This study will examine the efficacy of twice daily dosing of DMT210 topical gel in 104 moderate to severe acne rosacea patients with top-line results expected in Q3'17.

Read more here link.

2016 —

11.17.16 / Dermata Therapeutics, LLC Announces Initiation of Treatment in a Phase 2 Atopic Dermatitis Study.
Dermata dosed its first patient in a Phase 2 Atopic Dermatitis study with its lead compound DMT210.  The study will be conducted in 25 patients, each acting as their own control, to determine the efficacy and safety of DMT210.   

Read more here link

09.28.16 / Dermata Therapeutics, LLC Announces Positive Top-Line Results from their Phase 1 Pharmacokinetic Study of DMT210 in Acne Rosacea Patients.
Dermata received positive results in product safety, tolerability and efficacy from their 28-day Phase 1 study in rosacea patients. These results will help the company move into their upcoming Phase 2 studies in both rosacea and atopic dermatitis.   

Read more here link.

09.20.16 / Dermata Therapeutics, LLC Announced the Addition of Wendell Wierenga, Ph.D. to its Board of Directors.
Dr. Wierenga's addition to Dermata's Board of Directors brings broad R&D experience in all therapeutic categories from both small and large companies.  Dr. Wierenga has been a member of the executive team and board of directors for multiple successful biotech companies and will provide a valuable perspective into Dermata's current development programs.   

Read more here link.

05.16.16 / Dermata Therapeutics, LLC Announces Initiation of Phase 1 Pharmacokinetic Study.
Dermata initiated its Phase 1 Pharmacokinetic Study in rosacea patients.  The study is designed to evaluate the pharmacokinets and safety of the lead compound DMT210, while also providing an early assessment of the efficiency of the product in patients suffering from rosacea.   

Read more here link.